In the opening weeks of 2019, pharma companies have boosted list prices on hundreds of treatments, including widely used painkillers and cardiovascular drugs. (Photo: Shutterstock)
Two years ago, fear that Donald Trump would clamp down on drug prices roiled the health industry's biggest annual gathering.
Now, pushback on prices has become part of a new normal for which many pharmaceutical executives have developed a reliable script: Drug costs should reflect the value treatments deliver to patients, they say. Savings shouldn't come at the expense of innovation. And the companies they run have been restrained and transparent in taking price increases.
In response, the Trump administration and Congress are gearing up for a renewed campaign to bring the companies to heel. The top U.S. health official said Wednesday that prices must come down, while lawmakers prepared to roll out new proposals to limit increases.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
